(December 20, 2019, 1:01 PM EST) -- ALEXANDRIA, Va. — A patent used in three Novo Nordisk A/S diabetes drugs would have been obvious to a person of skill in the art (POSA), a petitioner for inter partes review (IPR) told the Patent Trial and Appeal Board on Dec. 19 (Mylan Institutional LLC v. Novo Nordisk A/S, No. IPR2020-00324, PTAB)....